A Phase 1 Dose Escalation and Cohort Expansion Study of TSR-042, an Anti-PD-1 Monoclonal Antibody, in Patients With Advanced Solid Tumors
Why Is The garnet Study Being Done?
TSR-042 is an investigational immunotherapy drug called a PD-1 inhibitor. This trial will look at how safe and effective TSR-042 is in the treatment of advanced solid tumors.
- Patient with advanced or metastatic Non-Small Cell Lung Cancer, Endometrial cancers, and MSI-H solid tumors and has disease progression after treatment with available therapies that are known to confer clinical benefit or who are intolerant to treatment.
- Women who are able to become pregnant must have a negative serum pregnancy test within 72 hours before the date of the first dose of study medication.
- Have been treated with any of the following classes of drugs: anti-PD-1, anti-PD-L1, or anti-PD- L2.
- Known additional cancer that progressed or needed treatment within the last 2 years. Exceptions include basal cell cancer of the skin, squamous cell cancer of the skin that has been treated with potentially helpful therapy, or early stage cervical cancer.
- Active hepatitis B or hepatitis C; known history of HIV (human immunodeficiency virus).
How Do I Know if the Garnet Trial is Right for Me?
The best next step is to contact the research site that would be the most convenient for you in order to discuss your medical history and whether the GARNET clinical trial would be a good fit.
To find sites in your area, contact: firstname.lastname@example.org or use the form above.
To find additional information on GARNET see: clinicaltrials.gov